Diamonds and Dogs
Clovis Oncology (CLVS) found a four leaf clover. The drug company is surging 43% following positive phase 3 drug data for ovarian cancer. Based on this data, Clovis will submit a supplemental New Drug Application within the next four months for a second-line and later maintenance treatment. The stock was upgraded following the data from a sell to a buy with a $50 price target. The stock is currently $84 a share.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.